Tempus Stock

tempus.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $1.08B

Tempus is a biotechnology company that uses AI-driven precision medicine. By deriving insights from a library of clinical data and molecular data, Tempus has a mission to build personalized healthcare data to support diagnostics in cardiology, neuropsychiatry, radiology, and infectious diseases. The goal of Tempus is to help patients live longer lives, backed by machine learning tools and technology. Tempus was founded by Eric Lefkofsky in 2015 and is headquartered in Chicago, IL.

Register To Buy and Sell Shares

For more details on financing and valuation for Tempus, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Tempus’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Tempus.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Kevin White, Ph.D.
Chief Science Officer
Vanessa Rollings
Chief Financial Officer
Eric Lefkofsky
Founder & Chief Executive Officer
Ryan Fukushima
Chief Operating Officer
Marc Yoskowitz
Chief Strategy Officer
Mike Yasiejko
Chief Commercial Officer
Gary Palmer, MD
Chief Medical Officer
Shane Colley
Chief Technology Officer
Chief Strategy Officer
Chief People Officer

Board Members

David Agus, MD
A. Keith Stewart, MB.CHB., MBA
Steve Case
Arul M. Chinnaiyan, MD, Ph.D.
Peter Barris
New Enterprise Associates
Funmi Olopade, MD
Eric Topol, MD
John Doerr
Kleiner Perkins

Frequently Asked Questions About Tempus’ Stock

Can you buy Tempus’ stock?
Tempus is not publicly traded on NYSE or NASDAQ in the U.S. To buy Tempus’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Tempus’ stock?
Yes, you can sell stock of a private company like Tempus. Forge can help you sell your Tempus stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Tempus’ stock price?
Tempus is a privately held company and therefore does not have a public stock price. However, you may access Tempus’ private market stock price with Forge Data.
What is Tempus’ stock ticker symbol?
Tempus does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

SkylineDx Announces Commercial Collaboration with Tempus to Advance Patient Care with its Merlin Test
Tempus, a biotechnology research company providing physicians with AI-enabled medicine solutions, is collaborating with SkylineDx to make their Merlin Test more accessible to melanoma cancer patients in the U.S. The test assesses the metastasis risk on a patient’s sentinel lymph nodes based on genes from the main tumor, tumor thickness, and the patient’s age. The collaboration between Tempus and SkylineDx will give healthcare providers better insights into early-stage treatment options depending on each patient’s need.
Tempus, Pyramid Biosciences to ID Patients With NTRK Fusion-Driven Cancers for Clinical Trial
Pyramid will use Tempus' TIME Trial Network to identify and enroll patients eligible for a Phase I/II trial of its TRK inhibitor, PBI-200.
Illinois cruise passengers can't come home yet • Layoffs at Weiss, West Suburban • Tempus to expand beyond cancer
Updated on: May 22, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.